Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Frank Grollman"'
Autor:
Rebecca R. Thomas, J. Michael Hamilton, Elizabeth B. Agnew, Jean L. Grem, Geraldine Morrison, Chris H. Takimoto, Frank Grollman, Louise Grochow, Eva Szabo, Xiao Du Guo, Len Neckers, Richard H. Wilson
Publikováno v:
Journal of Clinical Oncology. 23:1885-1893
Purpose To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks. Patients and Methods Nineteen patients received 17-AAG over six dose levels (10 to 56 mg/m2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08ec9755e546fd5b3041848629ccbde9
https://doi.org/10.1200/jco.2005.12.085
https://doi.org/10.1200/jco.2005.12.085
Autor:
Jean L. Grem, Aaron Ernst, Maurice A. Wright, Vivian Kao, Ilan R. Kirsch, Allison Parr, Liam Grogan, Abdel Salam Attia Ismail, Frank Grollman, Mary G. Quinn
Publikováno v:
Oncology Reports.
We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon alpha-2a (IFN-alpha). This phase II study assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::454c934812ff4ab9c715e3925d75de1d
https://doi.org/10.3892/or.13.6.1145
https://doi.org/10.3892/or.13.6.1145
Autor:
Abdel Salam Attia, Ismail, Mary G, Quinn, Maurice A, Wright, Aaron, Ernst, Vivian, Kao, Liam, Grogan, Allison, Parr, Frank, Grollman, Ilan R, Kirsch, Jean L, Grem
Publikováno v:
Oncology reports. 13(6)
We have reported that increasing the length of infusion from 5 min to 1 h appeared to substantially reduce the toxicity associated with fluorouracil (5-FU) modulated by leucovorin (LV) and interferon alpha-2a (IFN-alpha). This phase II study assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cd63def07ea94be79c5179186a0960dc
https://pubmed.ncbi.nlm.nih.gov/15870935
https://pubmed.ncbi.nlm.nih.gov/15870935
Autor:
Frank Grollman, J M Hamilton, Jean L. Grem, Lorrin K. Yee, Chris H. Takimoto, Carmen J. Allegra, C. Chabuk, Alice P. Chen, M. Grabenc, Barbara Schuler
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(11)
Background: We have reported that N-(phosphonacetyl)-L-aspartic acid (PALA) 1266 mg/m 2 can safely be given 24 hours prior to the start of a 72-hour infusion of fluorouracil (FUra) and leucovorin (LV) at doses of 2000 and 500 mg/m 2 /day. Since inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a021c9945813ec85f746b36dd06527
https://pubmed.ncbi.nlm.nih.gov/11822758
https://pubmed.ncbi.nlm.nih.gov/11822758
Autor:
Sean Donavan, Jean L. Grem, Dao-Qin Bi, Chris H. Takimoto, Nancy Harold, Frank Grollman, Geraldine Morrison, Brian P. Monahan, Jeremy Shapiro, Bruce Keith, J. Michael Hamilton, Suzanne Zentko, Mary G. Quinn
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(23)
PURPOSE: Fluorouracil (5-FU) given as a weekly, high-dose 24-hour infusion is active and tolerable. We evaluated an oral regimen of eniluracil (which inactivates dihydropyrimidine dehydrogenase [DPD]), 5-FU, and leucovorin to simulate this schedule.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::491fc9cd2dc160077f6cdf2dd19ce5b3
https://pubmed.ncbi.nlm.nih.gov/11099325
https://pubmed.ncbi.nlm.nih.gov/11099325
Autor:
H Nakashima, Carmen J. Allegra, Nancy Harold, Ronald Lieberman, Chris H. Takimoto, Frank Grollman, Michael D. Liang, J M Hamilton, William L. Dahut, Jean L. Grem, W. Corse, Susan G. Arbuck, M Sorensen, Alice P. Chen
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 14(4)
PURPOSE To conduct a phase I and pharmacologic study of the new topoisomerase I inhibitor, 9-aminocamptothecin (9-AC). PATIENTS AND MATERIALS A 72-hour infusion of 9-AC was administered every 14 days to 48 solid-tumor patients at doses of 5 to 59 mic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f86099ee29eb12400223034b77d8b57
https://pubmed.ncbi.nlm.nih.gov/8648379
https://pubmed.ncbi.nlm.nih.gov/8648379
Autor:
Sarah Bernstein, B. Gause, Antoun Toubaji, M. S. Achtar, Michael Hamilton, R. Berhens, Samir N. Khleif, V. E. Herrin, Frank Grollman
Publikováno v:
Journal of Clinical Oncology. 25:3067-3067
3067 Background: Mutant ras oncogenes produce novel proteins that are processed and displayed through HLA molecules on tumor cells. Therefore, mutant ras is an attractive target for vaccine therapy. We have shown in a previous phase I trial that vacc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f25d8db0398bf1b85fe09b9d3260f9f
https://doi.org/10.1200/jco.2007.25.18_suppl.3067
https://doi.org/10.1200/jco.2007.25.18_suppl.3067
Autor:
Jay A. Berzofsky, Samir N. Khleif, B. Gause, D. Contoise, Seth M. Steinberg, V. E. Herrin, Frank Grollman, Sarah Bernstein, M. S. Achtar, Ramy Ibrahim
Publikováno v:
Journal of Clinical Oncology. 23:2508-2508
2508 Background: Cervical cancer is the second leading cause of cancer deaths amongst women. Despite the success of early discovery, some patients still present with metastatic disease. More than 9...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62811ad8b55c0435a340c621da598105
https://doi.org/10.1200/jco.2005.23.16_suppl.2508
https://doi.org/10.1200/jco.2005.23.16_suppl.2508